Approaches to the prevention of cardiotoxicity in patients with oncological disease
https://doi.org/10.18087/cardio.2514
Abstract
Patients with cancer have high risk of cardiovascular complications. They may be caused by tumor and cancer therapy. The possible approaches to the prevention of cardiotoxicity are discussed in this article: risk factors assessment, laboratory and instrumental diagnostics, non-pharmacological and pharmacological interventions.
About the Authors
O. V. Evsina
Ryazan State Medical University
Russian Federation
Vysokovoltnaya 9, Ryazan 390026, Russia
Russian Federation
Vysokovoltnaya 9, Ryazan 390026, Russia
D. V. Seliverstova
Ryazan State Medical University
Russian Federation
Vysokovoltnaya 9, Ryazan 390026, Russia
Russian Federation
Vysokovoltnaya 9, Ryazan 390026, Russia
References
1. Kulikov E. P., Ryazantsev M. E., Zubareva E. P., Sudakov I. B., Kaminskyi Yu. D., Sudakov A. I. et al. Dynamics of morbidity and mortality from malignant neoplasms in the Ryazan region 2004–2014. I. P. Pavlov Russian Medical Biological Herald. 2015;23 (4):109–15.. DOI: 10.17816/PAVLOVJ20154109–115
2. Health in Russia. 2017: statistical compendium. – M.: Rosstat, 2017. – 170 p.. ISBN978-5-89476-448-1
3. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Kaprin A. D., Stalinskiy V. V., Petrova G. V. – M.: MNIO them. P. A. Herzen – branch FGBU “NERC” Ministry of health of Russia, 2017. – 250p.. ISBN 978-5-85502-227-8
4. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer. 2013;49 (6):1374–403. DOI: 10.1016/j.ejca.2012.12.027
5. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T et al. Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians. 2012;62 (4):220–41. DOI: 10.3322/ caac.21149
6. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT et al. Chronic Health Conditions in Adult Survivors of Childhood Cancer. New England Journal of Medicine. 2006;355 (15):1572–82. DOI: 10.1056/NEJMsa060185
7. Limat S, Daguindau E, Cahn J-Y, Nerich V, Brion A, Perrin S et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma. Journal of Clinical Pharmacy and Therapeutics. 2014;39 (2):168–74. DOI: 10.1111/jcpt.12124
8. Hall PS, Harshman LC, Srinivas S, Witteles RM. The Frequency and Severity of Cardiovascular Toxicity from Targeted Therapy in Advanced Renal Cell Carcinoma Patients. JACC: Heart Failure. 2013;1 (1):72–8. DOI: 10.1016/j.jchf.2012.09.001
9. Semiglazova T. Y., Teletaeva G. M., Kozyavin N. A., Zagatina A. V. Diagnosis and prevention of cardiotoxicity in patients with breast cancer from the standpoint of an oncologist and a cardiologist. Tumors of female reproductive system. 2017;13 (3):17– 27.. DOI: 10.17650/1994-4098-2017-13-3-17-27
10. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal. 2016;37 (36):2768– 801. DOI: 10.1093/eurheartj/ehw211
11. Ewer MS, Ewer SM. Erratum: Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology. 2015;12 (11):620–620. DOI: 10.1038/nrcardio. 2015.133
12. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the esc committee for practice guidelines. Russian Journal of Cardiology. 2017;3 (143):105–39.. DOI: 10.15829/1560-4071-2017-3-105-139
13. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2014;27 (9):911–39. DOI: 10.1016/j.echo.2014.07.012
14. Cardinale D, Colombo, A, Lamantia, G, Colombo, N, Civelli, M, De Giacomi, G. Cardio-oncology: A new medical issue. ecancermedicalscience. 2009; DOI: 10.3332/ecancer.2008.126
15. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardiooncology and cardio-oncological prevention. Journal of the National Cancer Institute. 2010;102 (1):14–25. DOI: 10.1093/jnci/djp440
16. Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31 (29):3673–80. DOI: 10.1200/JCO.2013.49.3205
17. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardio-toxicity: revisited. Expert Opinion on Drug Safety. 2009;8 (2):191– 202. DOI: 10.1517/14740330902733961
18. Khouri MG, Douglas PS, Mackey JR, Martin M, Scott JM, Scherrer-Crosbie M et al. Cancer Therapy-Induced Cardiac Toxicity in Early BreastCancer:AddressingtheUnresolvedIssues.Circulation.2012;126 (23):2749–63. DOI: 10.1161/CIRCULATIONAHA.112.100560
19. Vitsenya M. V., Ageev F. T., Ovchinnikov A. G., Orlova R. V., Poltavskaya M. G., Sycheva E. A. Practical recommendations for the correction of cardiovascular toxicity of anticancer drug therapy. Malignant tumors: practical recommendations RUSSCO. 2017. P. 496–513.. DOI: 10.18027/2224–5057–2017–7–3s2–496–513
20. Chow EJ, Chen Y, Kremer LC, Breslow NE, Hudson MM, Armstrong GT et al. Individual Prediction of Heart Failure Among Childhood Cancer Survivors. Journal of Clinical Oncology. 2015;33 (5):394–402. DOI: 10.1200/JCO.2014.56.1373
21. Ezaz G, Long JB, Gross CP, Chen J. Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer. Journal of the American Heart Association. 2014;3 (1): e000472 – e000472. DOI: 10.1161/JAHA.113.000472
22. Fernández AE. Chemotherapy-induced dysfunction. E-Journal of Cardiology Practice. 2017;14 (40)
23. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging. 2014;15 (10):1063–93. DOI: 10.1093/ehjci/jeu192
24. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2013;26 (5):493–8. DOI: 10.1016/j.echo.2013.02.008
25. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. European Journal of Echocardiography. 2008;10 (2):165–93. DOI: 10.1093/ejechocard/jep007
26. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125 (17):2128–37. DOI: 10.1161/CIRCULATIONAHA.111.079921
27. Authors/Task Force Members, Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G et al. Guidelines on the management of valvular heart disease (version 2012). European Heart Journal. 2012;33 (19):2451–96. DOI: 10.1093/eurheartj/ehs109
28. 2006 writing committee members, Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Managementof Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Th acic Surgeons. Circulation. 2008;118 (15): e523–661. DOI: 10.1161/CIRCULATIONAHA.108.190748
29. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36 (42):2921–64. DOI: 10.1093/eurheartj/ehv318
30. Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM et al. American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. Journal of the American Society of Echocardiography. 2008;21 (11):1179–201. DOI: 10.1016/j.echo.2008.09.009
31. Writing/steering committee members, Douglas PS, Carr JJ, Cerqueira MD, Cummings JE, Gerber TC et al. Developing an Action Plan for Patient Radiation Safety in Adult Cardiovascular Medicine: Proceedings from the Duke University Clinical Research Institute/American College of Cardiology Foundation/American Heart Association Think Tank Held on February 28, 2011. Circulation: Cardiovascular Imaging. 2012;5 (3):400–14. DOI: 10.1161/HCI.0b013e318252e9d9
32. Yeh ETH, Bickford CL. Cardiovascular Complications of Cancer Therapy. Journal of the American College of Cardiology. 2009;53 (24):2231–47. DOI: 10.1016/j.jacc.2009.02.050
33. Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO, Myers CE, Barr LH et al. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Annals of Internal Medicine. 1981;94 (4 pt 1):430–5. PMID: 7212498
34. Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Manatunga A et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. The American Journal of Medicine. 1987;82 (6):1109–18. DOI: 10.1016/0002–9343(87)90212–9
35. Klein C, Nekolla SG, Bengel FM, Momose M, Sammer A, Haas F et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation. 2002;105 (2):162–7. PMID: 11790695
36. Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, JeroschHerold M, Francis SA et al. Left Ventricular Mass in Patients with a Cardiomyopathy After Treatment With Anthracyclines. Th American Journal of Cardiology. 2012;110 (11):1679–86. DOI: 10.1016/j.amjcard.2012.07.040
37. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Journal of Cardiovascular Magnetic Resonance: Offi ial Journal of the Society for Cardiovascular Magnetic Resonance. 2004;6 (4):727–65. PMID: 15646878
38. Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B et al. American Society of Echocardiography Clinical Recommendations for Multimodality Cardiovascular Imaging of Patients with Pericardial Disease. Journal of the American Society of Echocardiography. 2013;26 (9):965–1012. e15. DOI: 10.1016/j.echo.2013.06.023
39. Cardinale D, Sandri MT. Role of Biomarkers in Chemotherapy-Induced Cardiotoxicity. Progress in Cardiovascular Diseases. 2010;53 (2):121–9. DOI: 10.1016/j.pcad.2010.04.002
40. Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Annals of Hematology. 2003;82 (4):218–22. DOI: 10.1007/s00277-003-0615-3
41. Cardinale D. Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy. Circulation. 2004;109 (22):2749–54. DOI: 10.1161/01.CIR.0000130926.51766.CC
42. Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M et al. Serial measurements of NT-proBNP are predictive of nothigh-dose anthracycline cardiotoxicity in breast cancer patients. British Journal of Cancer. 2011;105 (11):1663–8. DOI: 10.1038/bjc.2011.439
43. Knobloch K, Tepe J, Lichtinghagen R, Luck HJ, Vogt PM. Monitoring of cardiotoxicity during immunotherapy with Herceptin using simultaneous continuous wave Doppler depending on N-terminal pro-brain natriuretic peptide. Clinical Medicine (London, England). 2007;7 (1):88–9; author reply 89. PMID: 17348585
44. Knobloch K, Tepe J, Rossner D, Lichtinghagen R, Luck HJ, Busch KH et al. Combined NT – pro-BNP and CW-Doppler ultrasound cardiac output monitoring (USCOM) in epirubicin and liposomal doxorubicin therapy. International Journal of Cardiology. 2008;128 (3):316– 25. DOI: 10.1016/j.ijcard.2007.04.182
45. Pun SC, Neilan TG. Cardioprotective Interventions: Where Are We? [Internet 2016. Available at: https://www.acc.org/latest-in-cardiology/articles/2016/07/21/07/28/cardioprotective-intervention
46. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M et al. Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition. Circulation. 2006;114 (23):2474–81. DOI: 10.1161/CIRCULATIONAHA.106.635144
47. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessì M, Madeddu C et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. American Heart Journal. 2010;160 (3):487. e1–487. e7. DOI: 10.1016/j.ahj.2010.05.037
48. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, doubleblind clinical trial of candesartan and metoprolol. European Heart Journal. 2016;37 (21):1671–80. DOI: 10.1093/eurheartj/ehw022
49. Bernstein D, Fajardo G, Zhao M, Urashima T, Powers J, Berry G et al. Differential cardioprotective/cardiotoxic effects mediated by β-adrenergic receptor subtypes. American Journal of PhysiologyHeart and Circulatory Physiology. 2005;289 (6):H2441–9. DOI: 10.1152/ajpheart.00005.2005
50. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. Journal of the American College of Cardiology. 2006;48 (11):2258–62. DOI: 10.1016/j.jacc.2006.07.052
51. Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study. International Journal of Cardiology. 2013;167 (5):2306–10. DOI: 10.1016/j.ijcard.2012.06.023
52. Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: A prospective, parallel-group, randomized, controlled study with 36-month follow-up. American Journal of Hematology. 2010;85 (11):894–6. DOI: 10.1002/ajh.21840
53. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S et al. Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy. Journal of the American College of Cardiology. 2011;58 (9):988–9. DOI: 10.1016/j.jacc.2011.05.025
54. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM et al. Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies. Journal of the American College of Cardiology. 2013;61 (23):2355–62. DOI: 10.1016/j.jacc.2013.02.072
55. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101 – Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology. 2017;35 (8):870–7. DOI: 10.1200/JCO.2016.68.7830
56. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. European Heart Journal Cardiovascular Imaging. 2014;15 (3):324–31. DOI: 10.1093/ehjci/jet159
57. van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews. 2008; (2):CD003917. DOI: 10.1002/14651858.CD003917.pub3.
58. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D et al. Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2 – Overexpressing Breast Cancer: NSABP B-31. Journal of Clinical Oncology. 2005;23 (31):7811– 9. DOI: 10.1200/JCO.2005.02.4091
59. Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clinical Pharmacokinetics. 2017;56 (12):1461–78. DOI: 10.1007/s40262-017-0543-3
60. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet. 2010;376 (9744):875–85. DOI: 10.1016/S0140–6736(10)61198–1
61. Vasyuk Yu.V., Nesvetov V.V., Shkolnik E.L., Shkolnik L.D., Varlan G.V., Gendlin G.E. et al. Possibilities of ivabradine, a selective inhibitor of ion f-channels of sinus node, in prevention of anthracycline cardiotoxicity in patients with breast cancer. Rational Pharmacotherapy in Cardiology. 2017;13 (2):184–90.. DOI: 10.20996/1819-6446-2017-13-2-184-190
62. Cadeddu C, Mercurio V, Spallarossa P, Nodari S, Triggiani M, Monte I et al. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies. Journal of Cardiovascular Medicine. 2016;17: e64–75. DOI: 10.2459/JCM.0000000000000382
63. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and Management of Patients with Heart Disease and Cancer: Cardio-Oncology. Mayo Clinic Proceedings. 2014;89 (9):1287–306. DOI: 10.1016/j.mayocp.2014.05.013
64. Norman HA, Butrum RR, Feldman E, Heber D, Nixon D, Picciano MF et al. The Role of Dietary Supplements during Cancer Therapy. The Journal of Nutrition. 2003;133 (11):3794S-3799S. DOI: 10.1093/jn/133.11.3794S
65. Yakushin S. S., Filippov E. V. The main directions of the primary prevention of cardiovascular disease. Nauka molodykh (Eruditio Juvenium). 2014;4:55–68.
66. Hayes SC, Spence RR, Galvão DA, Newton RU. Australian Association for Exercise and Sport Science position stand: Optimising cancer outcomes through exercise. Journal of Science and Medicine in Sport. 2009;12 (4):428–34. DOI: 10.1016/j.jsams.2009.03.002
67. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database of Systematic Reviews. 2012; DOI: 10.1002/14651858.CD008465.pub2
Review
For citations:
Evsina O.V., Seliverstova D.V. Approaches to the prevention of cardiotoxicity in patients with oncological disease. Kardiologiia. 2018;58(11S):4-13. (In Russ.) https://doi.org/10.18087/cardio.2514
Views:
1649
Email this article 
Post a Comment 
